A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
نویسندگان
چکیده
Methods 610 patients (≥12 years old) with moderate-to-severe SAR were randomized into a double-blind, placebo-controlled, 14-day, parallel-group trial to MP29-02*, AZE or FP nasal sprays and placebo (all given as 1 spray/nostril bid; total daily dose: 548μg AZE, 200μg FP]. Patients were defined as ‘nasal congestion predominants’ if their maximum symptom score at baseline was the nasal congestion score (n=368). Both reflective total nasal symptom score (rTNSS; max score =24) and nasal congestion symptom score (max score =6) reduction were assessed in these patients to show effect on their overall nasal symptom burden, as well as specific relief from nasal congestion.
منابع مشابه
A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
Background Allergic rhinitis (AR) patients often present with a predominant symptom. Nasal congestion and ocular symptoms have the greatest negative impact on patients’ quality of life [1]. Our aim was to assess the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride [AZE] and fluticasone propionate [FP] in an advanced delivery system) in seasonal AR (SAR) patients ...
متن کاملEscaping the trap of allergic rhinitis
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become 'intolerable' and often when their usual therapy proves ineffec...
متن کاملThe journey from unmet need in allergic rhinitis to rationale for, and clinical development of, a new treatment option, MP29-02
• Currently considered first-line allergic rhinitis (AR) therapy provides insufficient symptom relief for many AR patients. • MP29-02 (Dymista®, Meda AB, Solna, Sweden) is a new intranasal AR therapy, consisting of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel and patented formulation and advanced device. • It is indicated for the symptomatic relief of moderate/sever...
متن کاملA new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
Methods Six hundred and ten moderate-to-severe SAR patients (≥12 yrs) were randomized into a double-blind, PLAcontrolled, 14-day, parallel-group, trial (NCT00660517) to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/ nostril bd; daily dose: AZE=548μg; FP=200μg) [1]. Change from baseline (CFB) in reflective total of 7 symptom scores (rT7SS; AM + PM, max=42) was assessed post-hoc. CFB in rT7SS an...
متن کاملA new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
Background Over 90% of allergic rhinitis (AR) patients have ocular symptoms during the pollen season, but these are routinely neglected and under-treated. New treatment options should provide relief not only from all nasal symptoms, but all ocular symptoms too, since patients frequently present with symptoms from both nasal and ocular origin. The reflective total of 7 symptom scores (rT7SS) is ...
متن کامل